



Agile Therapeutics  
Investor Relations Department  
101 Poor Farm Road  
Princeton, NJ 08540  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

#### NASDAQ: AGRX

Last Trade:	3.30
Trade Time:	3:23 PM ET Jan 17, 2018
Change:	-0.19 <span style="color:red">▼</span> (-5.444%)
Day Range	3.23 - 3.64
52-Week Range	1.93 - 5.60
Volume	401,354

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## Stock Performance



### Press Releases [\[ View all \]](#)

- Dec 22, 2017*  
[Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® \(AG200-15\) for the Prevention of Pregnancy](#)
- Nov 6, 2017*  
[Agile Therapeutics Reports Third Quarter 2017 Financial Results](#)
- Oct 31, 2017*  
[Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine \(ASRM\) Scientific Congress & Expo 2017](#)
- Oct 16, 2017*  
[Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017](#)
- Oct 10, 2017*  
[Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy](#)

### Financials [\[ View all \]](#)

- Mar 15, 2017*  
[Annual Report \(10-K\)](#)
- Apr 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 28, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)